Industry News
The latest pharmaceutical and supplement industry news — regulation updates, safety alerts, market trends, and research breakthroughs.
FDA Issues Warning Letter Over Serious Manufacturing Violations
FDA warns American Pharma Manufacturing after March 2026 inspection revealed critical quality control failures and Current Good Manufacturing Practice violations.
FDA Approves First Once-Weekly Insulin for Type 2 Diabetes
FDA grants approval to Onswik (insulin efsitora alfa-gobe), the first once-weekly insulin therapy for Type 2 Diabetes, marking a potential paradigm shift in treatment adherence.
Polypharmacy Surge Among Older Americans Reveals Drug Interaction Risks
New research shows polypharmacy increasing among seniors while OTC use declines, raising concerns about dangerous drug-drug interactions in this vulnerable population.
FDA Approves First-Ever Treatment for MCT8 Deficiency
FDA's landmark September 28, 2026 approval marks the first treatment for MCT8 deficiency, a rare genetic disorder affecting thyroid hormone transport to the brain.
Drug Repurposing Market Hits $29.4B as Industry Seeks Cost Relief
The drug repurposing market reached $29.4B in 2024, offering pharma companies a cost-effective R&D alternative amid rising development costs and tariff pressures.
FDA Elevates Thyroid Medication Recall to Class I Over Overdose Risk
Vitrivious Therapeutics' thyroid tablets upgraded to highest FDA recall classification after suprapotent hormone levels discovered, raising cardiac risks.
AstraZeneca Bets $2B on Summit Therapeutics in Major Oncology Play
AstraZeneca's unprecedented $2 billion equity stake in Summit Therapeutics signals a strategic shift in pharma partnerships and confidence in next-generation cancer therapies.
OpenAI Unveils GPT-Rosalind: Frontier AI Model for Drug Discovery
OpenAI's new GPT-Rosalind model targets pharmaceutical R&D with specialized capabilities in drug discovery, genomics analysis, and protein reasoning.
FDA Confirms Widespread Drug Contamination in Dietary Supplements
New Harvard research and FDA testing reveal prescription drugs and heavy metals in popular supplements, raising urgent safety concerns for millions of consumers.
Pharmaceutical Fine Chemicals Market Surges to $179.87B in 2026
The pharmaceutical fine chemicals sector is experiencing exceptional growth, with market value jumping $15B to reach $179.87B in 2026, signaling robust drug manufacturing expansion.
GLP-1 Powder Supplements Spark Safety Concerns Amid Regulatory Gap
Health experts warn consumers about unregulated GLP-1 powder supplements flooding the market as demand surges during branded drug shortages, raising serious safety questions.
Dietary Supplements Market Set to Reach $324.88B by 2034
New market analysis projects the global dietary supplements industry will grow at 6.37% annually through 2034, driven by consumer wellness trends and aging populations.
Big Pharma Turns to China for Next-Gen Cancer Drug Innovation
Major pharmaceutical companies are increasingly licensing oncology compounds from Chinese biotech firms, signaling a strategic shift in global drug development sourcing.
GSK's $110M AI Partnership Signals New Era in Drug Discovery
GSK's collaboration with Relation Therapeutics, valued up to $110M, represents pharmaceutical industry's accelerating shift toward AI-driven research platforms.
Cell Culture Supplements Market Set to Triple by 2033 on Biotech Boom
Cell culture supplements market projected to surge from $2.74B to $7.14B by 2033, driven by biopharmaceutical manufacturing expansion and cell therapy development.
Main Street Pharmacy Access Act Advances Pharmacist Authority
Federal legislation aims to expand pharmacist practice authority nationwide, but experts warn workforce readiness must match new statutory powers.
FDA Issues Seven Alerts on Weight-Loss Supplements with Hidden Toxins
Federal regulators have escalated enforcement against weight-loss supplements containing undeclared hazardous substances including industrial chemicals and withdrawn drugs.
FDA Launches Expedited IND Pilot to Accelerate Clinical Trials
The FDA's new Expedited IND Pilot Program pairs sponsors with research institutions to reduce early-phase trial delays, potentially shortening drug development timelines.
FDA Launches Glutathione Injection Safety Investigation
CDC and FDA investigate adverse events from contaminated compounded glutathione injections after three recalls for endotoxin contamination expose regulatory gaps.
FDA Issues Emergency Guidance on Hospital Ibuprofen Compounding
FDA allows hospitals to compound ibuprofen suspension addressing pediatric fever treatment and swallowing difficulties amid supply shortages—a significant shift in policy.